IIL begins supply of Covaxin drug substance to Bharat Biotech
The Hindu
Output to be 3-4 million doses a month and increase to 10 million doses a month from December
Vaccine maker Indian Immunologicals (IIL) on Friday handed the first lot of Covaxin drug substance to Bharat Biotech. A development expected to pave the way for augmenting the indigenous COVID-19 vaccine production, it follows the Centre, in April this year, mooting a collaboration between IIL and Bharat Biotech. Several activities were performed in a short period of time, IIL said in a release. These signing of four agreements with Bharat Biotech, repurposing of the IIL manufacturing facility in Hyderabad, procurement of key raw materials, consumables and equipment for the process as well as technology transfer, trials at research and development scale and training.More Related News

“Judicial time is a valuable public resource. Every frivolous or misconceived invocation of constitutional jurisdiction results in diversion of time from genuinely deserving litigants,” said the Madurai Bench of the Madras High Court while imposing a cost of ₹50,000 on a man from Theni district who filed a petition with an unusual prayer: permission to conduct daily protests till the ‘World War’ ends.












